BridgeBio Pharma (BBIO) said Monday acoramidis showed "statistically significant improvements" in clinical outcomes in both variant and wild-type transthyretin amyloid cardiomyopathy, or ATTR-CM, in a phase 3 trial.
The study compared acoramidis with placebo for time to all-cause mortality or first cardiovascular-related hospitalization in both variant and wild-type ATTR-CM, the company said.
Data showed that acoramidis increased serum transthyretin concentrations along with a 59.1% reduction in the risk of mortality or first hospitalization compared with placebo in patients with variant ATTR-CM, and 31.2% risk reduction in patients with wild-type ATTR-CM at month 30, according to the company.
Acoramidis also stabilized TTR levels in both patient groups, demonstrating over 90% stabilization, the company said.
Acoramidis is approved as Attruby in the US and as Beyonttra in the European Union and Japan.
Price: 34.62, Change: -0.49, Percent Change: -1.40
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.